Symbiosis confirms commitment to growth strategy with key appointment

Symbiosis StIrling

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

STIRLING-based Symbiosis Pharmaceutical Services has appointed a new chief operating officer.

John McCormick takes on the role at the firm which specialises in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals.

Previously operations development director at Symbiosis, John has 15 years of experience in the pharmaceutical and biotechnology industry in various roles including pharmaceutical formulation, medicine manufacturing process development, project technical transfer, manufacturing scale-up, and clinical and commercial manufacture of a number of dosage forms including capsules and injectables.   

As COO John, who also becomes an executive member of the board, will take operational leadership of the project management, quality, manufacturing, technical, supply chain, engineering, validation and training operational functions. 

He will continue to lead the ongoing implementation of Innovate UK grant projects currently being undertaken jointly by Symbiosis and its external collaborators who include Freeline Therapeutics and the Cell and Gene Therapy Catapult (CGTC) in Stevenage, UK. 

Colin MacKay, Symbiosis CEO, said: “Our expertise in small-to-medium scale clinical trial and commercial sterile manufacturing continues to resonate successfully with our target client market, as demonstrated by repeated annual business growth of around 25%. 

“Our recent successes in manufacturing COVID-19 candidate vaccine further underlines the competitive strengths of Symbiosis.

“John’s promotion and appointment to the board of directors is part of a long-term strategy to support the continued organic growth of our core sterile manufacturing services in the US and Europe and a reflection of his achievement to date, our success in the market, and my confidence in his abilities.”

“These are exciting times for Symbiosis and I look forward to playing a key role in the next chapter of the company’s rapid development. Together with the CEO, Board of Directors and senior management team, I will be focused on further developing our operational capacity and capability and ensuring that we continue to provide the world-class service that our clients have come to expect.”


Related News

Our brands